Rybrevant

Showing 2 posts of 2 posts found.

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024
Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

March 4, 2024
Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …

The Gateway to Local Adoption Series

Latest content